Cargando…
Evaluation of the Genotoxic Potential of the Selective COX-2 Inhibitor Enflicoxib in a Battery of in vitro and in vivo Genotoxicity Assays
Aim Enflicoxib, a selective COX-2 inhibitor approved for the treatment of pain and inflammation associated with osteoarthritis in dogs (Daxocox (®) [Ecuphar/Animalcare Group]) was assessed for its genotoxic potential in a battery of in vitro and in vivo genotoxicity assays. These comprised a bacteri...
Autores principales: | Guzmán, Antonio, Homedes, Josep, Salichs, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900152/ https://www.ncbi.nlm.nih.gov/pubmed/35042267 http://dx.doi.org/10.1055/a-1727-5733 |
Ejemplares similares
-
Long-term safety evaluation of Daxocox(®) tablets (enflicoxib) in dogs after weekly oral administrations for seven months
por: Homedes, Josep, et al.
Publicado: (2021) -
Selective inhibition of cyclooxygenase‐2 by enflicoxib, its enantiomers and its main metabolites in vitro in canine blood
por: Solà, Josep, et al.
Publicado: (2022) -
Pharmacokinetics of enflicoxib in dogs: Effects of prandial state and repeated administration
por: Homedes, Josep, et al.
Publicado: (2021) -
Comparative In vitro Metabolism of Enflicoxib in Dogs, Rats, and Humans: Main Metabolites and Proposed Metabolic Pathways
por: Solà, Josep, et al.
Publicado: (2021) -
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib
por: Salichs, Marta, et al.
Publicado: (2022)